Page 102 - 《运动与健康科学》(英文)2024年第2期
P. 102

TaggedAPTARAFigure
         224                                                                                              X. Jin et al.
                                                                  TaggedAPTARAPSleep duration was obtained from the returned dataset of
                                                               UK Biobank (Return ID 1862). The procedures of data proce-
                                                               ssing and analyses were described previously. 26  Sleep periods
                                                               were defined using an automated detection algorithm 26,27
                                                               implemented in the GGIR R package 28  and validated using
                                                               polysomnography (PSG) in an external cohort. The algo-
                                                               rithm facilitates detection of the sleep period time window
                                                               (SPT-window) without the use of sleep diaries. The SPT-window
                                                               refers to the time window starting at sleep onset and ending
                                                               upon waking from the last sleep episode of the night. Sleep
                                                               episodes within the SPT-window were defined as periods of
                                                               5 min with no z-axis changes greater than 5˚. Sleep duration
                                                               for a given SPT-window was calculated by summing the dura-
                                                               tions of all sleep episodes within the SPT-window. The mean
                                                               sleep duration across all SPT-windows provided a measurement
                                                               of average sleep quantity. Due to the expected nonlinear associ-
                                                                                                            6,9
                                                               ation between sleep duration and type 2 diabetes risks,  we
                                                               further divided the participants into 3 groups with cutoffs based
                                                                               29
                                                               on previous studies  and the American Academy of Sleep
                                                               Medicine consensus 5  suggestion: short (<6 h/day), normal
                                                               (68h/day), andlongsleep duration(>8h/day).TaggedAPTARAEnd
                                                                  TaggedAPTARAPParticipants with at least 3 days of accelerometry data (Field
                                                               ID 90015) were included in the current study. This inclusion
                                                               criterion was defined by the UK Biobank accelerometer expert
                                                               working group, who found that 3 days of wear were needed to
                                                               be within 10% of a complete 7-day measure after performing
                                                               missing data simulations on 29,765 participants who had perfect
                                                               wear time compliance. 19  A total number of 4470 participants
                                                               were ruled out for not satisfying this inclusion criterion in the
                                                               current study (Fig. 1). Participants were also excluded if their
         Fig. 1. Flowchart of participant enrollment. HbA1c = glycated hemoglobin;  mean sleep duration was less than 3 or longer than 11 h (Fig. 1).
         LPA = light-intensity physical activity; MVPA = moderate-to-vigorous phys-  Participants included in the final sample had 6.93 valid days of
         ical activity; PA = physical activity.TaggedAPTARAEnd
                                                               accelerometer wearing on average.TaggedAPTARAEnd
         acceleration signals, 1 gravitational unit from the vector  TaggedAPTARAH22.3. OutcomesTaggedAPTARAEnd
         magnitude was removed, and the remaining negative values
                                                                  TaggedAPTARAPThe outcome of this study was incident type 2 diabetes, which
         were truncated to 0. PA was calculated from the resampled
                                                               was defined based on hospital records or death registry (Supple-
         data combined in 5-s epochs (Field ID 90004). Three cate-
                                                               mentary Table 1). The data on dates and causes of hospital
         gories of PA (total volume of PA, MVPA, and LPA) were
                                                               records for participants from Scotland were obtained from the
         included in the current study. The total volume of PA was
                                                               Scottish Morbidity Records, and those for participants from
         measured as the weekly average vector magnitude in milli-  England and Wales came from health episode statistics. The data
         gravity (mg) units (Field ID 90012). 21  MVPA was defined
                                                               on dates and causes of death for participants from England and
         as reaching the following standard: (a) within a 5-min
                                                               Wales were obtained from the death registries of the National
         period, over 80% of the 5-s epochs having a mean accelera-
                                                               Health Service Information Center, and those for participants
         tion between 100mg and 400mg (moderate-intensity PA,  from Scotland came from the National Health Service Central
         MPA); 22  or (b) any single 5-s epoch having a mean acceler-  Register Scotland. Further detailed information on linkage proce-
         ation >400mg (vigorous-intensity PA (VPA)). 21  LPA was
                                                               dures is available at http://content.digital.nhs.uk/services. At the
         defined as any single epoch with a mean acceleration of  time of analysis, hospital record data were available for partici-
         30100mg. 23  The amounts of MVPA and LPA (min/week)
                                                               pants until September 30, 2021, and death registry data were
         were calculated for each participant. Similarly, considering
                                                               available until November 12, 2021. Therefore, we used
         the expected nonlinear associations with type 2 diabetes  November 12, 2021 as the censor date unless hospital admission
         risks, 24  the total volume of PA and LPA was then divided
                                                               or death occurred first.TaggedAPTARAEnd
         into high and low groups according to the median, and
         MVPA was divided into recommended or not recommended
                                                               TaggedAPTARAH22.4. CovariatesTaggedAPTARAEnd
         groups according to the World Health Organization (WHO)
         guidelines (150 min of MPA, 75 min of VPA, or equiva-  TaggedAPTARAPThe following variables were considered likely confounding
                                                 25
         lent combinations of MPA and VPA per week). TaggedAPTARAEnd  factors: age at the time of accelerometer wearing (continuous,
   97   98   99   100   101   102   103   104   105   106   107